| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ASB13 |
| Uniprot No | Q8WXK3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-278aa |
| 氨基酸序列 | MNHKVHHHHHHMEPRAADGCFLGDVGFWVERTPVHEAAQRGESLQLQQLI ESGACVNQVTVDSITPLHAASLQGQARCVQLLLAAGAQVDARNIDGSTPL CDACASGSIECVKLLLSYGAKVNPPLYTASPLHEACMSGSSECVRLLIDV GANLEAHDCHFGTPLHVACAREHLDCVKVLLNAGANVNAAKLHETALHHA AKVKNVDLIEMLIEFGGNIYARDNRGKKPSDYTWSSSAPAKCFEYYEKTP LTLSQLCRVNLRKATGVRGLEKIAKLNIPPRLIDYLSYN |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ASB13重组蛋白的3篇代表性参考文献的简要概括(文献为假设示例，实际研究中请核实具体文献)：
---
1. **标题**: *ASB13 interacts with the E3 ubiquitin ligase complex to regulate protein degradation*
**作者**: Smith J, et al.
**摘要**: 本研究通过在大肠杆菌中表达并纯化重组ASB13蛋白，发现其SOCS结构域可直接结合E3泛素连接酶复合体，并通过泛素-蛋白酶体通路调控靶蛋白降解，揭示了ASB13在细胞蛋白稳态中的作用。
2. **标题**: *Structural and functional analysis of the Ankyrin repeats in ASB13*
**作者**: Zhang Y, et al.
**摘要**: 利用昆虫表达系统获得重组ASB13蛋白，通过X射线晶体学解析其Ankyrin重复结构域的三维结构，证明该区域对底物识别具有关键作用，为ASB13在肿瘤转移中的调控机制提供结构基础。
3. **标题**: *ASB13 suppresses TGF-β signaling by promoting Smad7 ubiquitination*
**作者**: Lee H, et al.
**摘要**: 通过哺乳动物细胞表达重组ASB13.发现其通过招募E3连接酶促进Smad7的泛素化降解，从而负调控TGF-β信号通路，表明ASB13可能作为癌症治疗的潜在靶点。
---
注：以上文献内容为基于ASB蛋白家族典型功能的模拟概括，实际研究需查阅具体数据库(如PubMed)以获取准确信息。
ASB13 (Ankyrin Repeat and SOCS Box Protein 13) is a member of the ASB family, characterized by tandem ankyrin repeats and a C-terminal SOCS box domain. The ankyrin repeats mediate protein-protein interactions, while the SOCS box recruits components of the E3 ubiquitin ligase complex, implicating ASB13 in substrate-specific protein ubiquitination and degradation via the proteasome. This dual-domain structure suggests a role in regulating cellular processes such as signal transduction, protein turnover, and metabolic homeostasis.
ASB13 is expressed in various tissues, with emerging evidence linking it to cancer, metabolism, and immune regulation. Studies indicate that ASB13 may act as a tumor suppressor in certain cancers by targeting oncoproteins for degradation. For example, it has been shown to interact with and destabilize c-Myc, a key regulator of cell proliferation. Conversely, dysregulation of ASB13 expression has been observed in metabolic disorders, suggesting involvement in energy balance pathways. Its precise physiological substrates and regulatory mechanisms, however, remain under investigation.
Recombinant ASB13 protein is engineered for in vitro studies to elucidate its structural and functional properties. Produced using expression systems like *E. coli* or mammalian cells, the recombinant form retains critical domains for interaction and ubiquitination activity. Researchers utilize it to map binding partners, characterize enzymatic functions, and explore therapeutic potential in disease models. Its application extends to drug discovery, particularly in designing molecules that modulate ubiquitination pathways. Despite progress, further research is needed to fully unravel ASB13's biological roles and its utility as a diagnostic or therapeutic target.
×
